Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-12), SymBio Pharmaceuticals's 3-1 Month Momentum % is -1.41%.
The industry rank for SymBio Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
TSE:4582's 3-1 Month Momentum % is ranked worse than 64.22% of 1023
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs TSE:4582: -1.41
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
SymBio Pharmaceuticals 3-1 Month Momentum % Related Terms
TSE:4582 vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals (TSE:4582) has a 3-1 Month Momentum % of -1.41% as of Sep. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SymBio Pharmaceuticals and its competitors. According to the industry distribution chart, SymBio Pharmaceuticals ranks #657 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 64.2%.
Is SymBio Pharmaceuticals' 3-1 Month Momentum % too high?
SymBio Pharmaceuticals' current 3-1 Month Momentum % is -1.41%. Based on the distribution chart, SymBio Pharmaceuticals ranks #657 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #657 out of 1023 companies for 3-1 Month Momentum %. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median 3-1 Month Momentum % is 3.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 3.13, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on SymBio Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current 3-1 Month Momentum % is -1.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Fairly Valued. The stock's GF Value™ is 円52.24, compared to a current price of 円57.00 — trading 9.1% above its estimated fair value. The current 3-1 Month Momentum % is -1.41%. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current 3-1 Month Momentum % is -1.41% as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of 円57.00 is trading 9.1% above its estimated GF Value™ of 円52.24.
GuruFocus considers SymBio Pharmaceuticals to be Fairly Valued.
Key valuation signals for TSE:4582:
3-1 Month Momentum %: -1.41%
GF Value™: 円52.24 vs. price of 円57.00 (9.1% above fair value)
No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score
Get the complete analysis for TSE:4582
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4582 has been successfully added to your 
